15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 12 firms covering 10X Genomics Inc, 4 rate it Buy or better, 8 sit at Hold, and 0 rate it Sell or worse, a hold consensus. Targets range widely, $19.00 to $50.00 (about 2.6x), a sign of real disagreement on valuation. The average target of $33.45 sits 27% below the current $45.92. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 1 to 0 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.04 next quarter toward $0.21 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 ratings
Hold
Strong Buy00%
Buy433%
Hold867%
Sell00%
Strong Sell00%
Based on 12 analysts giving stock ratings to 10X Genomics Inc.
As of Jul, 4 of 12 firms rate TXG a Buy (8 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TXG EPS & revenue forecast
EPS · NEXT QUARTER
$-0.04
Range $-0.06 – $-0.01 · 3 analysts · +61% YoY
Next period, 3 analysts expect 10X Genomics Inc to earn $-0.04 a share (range $-0.06 – $-0.01), versus $-0.02 a year earlier. Full-year consensus is $0.00, growing to $0.21 the year after.
REVENUE · NEXT QUARTER
$147.4M
Range $145.8M – $150.0M · 3 analysts · -1% YoY
Revenue is expected to reach $147.4M (range $145.8M – $150.0M), -1.1% year-over-year. Full-year consensus is $614.1M, rising to $671.5M next year.
Top analysts covering 10X Genomics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TXG.
#1
KM
Kyle Mikson
Canaccord Genuity · Rank #192
Buy
$50.00+8.9% to target
Overall win rate
35%
+ Follow
#2
Luke Sergott
Barclays · Rank #194
Buy
$40.00-12.9% to target
Overall win rate
41%
+ Follow
#3
David Westenberg
Piper Sandler · Rank #227
Hold
$42.00-8.5% to target
Overall win rate
31%
+ Follow
#4
Patrick Donnelly
Citigroup · Rank #260
Hold
$45.00-2.0% to target
Overall win rate
32%
+ Follow
#5
TS
Tejas Savant
Morgan Stanley
Hold
$37.00-19.4% to target
Coverage
—
+ Follow
TXG stock forecast FAQ
What is TXG's average 12-month price target?+
The 11 analysts with a live target average $33.45 for 10X Genomics Inc over the next 12 months, ranging from a $50.00 high to a $19.00 low.
Is TXG stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 12 analyst ratings, 4 are Buy or Strong Buy, 8 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for TXG?+
The Street-high target is $50.00 (Canaccord Genuity), and the Street-low is $19.00 (TD Cowen). The average of all 11 active targets is $33.45.
How many Wall Street analysts cover TXG?+
12 analysts have an active rating on 10X Genomics Inc, and 11 firms carry a live 12-month price target.
Who is the most accurate analyst covering TXG?+
Among analysts who currently cover TXG, Kyle Mikson of Canaccord Genuity has the strongest overall Quantellect track record (Rank #192). Their current call is Buy with a $50.00 target.
What is 10X Genomics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.04 per share (range $-0.06 – $-0.01) across 3 analysts. Full-year EPS is projected at $0.00, rising to $0.21 the following year.
How much revenue is 10X Genomics Inc expected to report next quarter?+
Consensus revenue is $147.4M (range $145.8M – $150.0M). Full-year revenue is projected at $614.1M, growing to $671.5M next year.
Have analysts been upgrading or downgrading TXG lately?+
As of Jul, 4 of 12 firms rate TXG a Buy (8 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TXG calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
